The biology of B cells that bear gain-of-function mutations in EZH2 make them predisposed to respond to EZH2 inhibitors; however, EZH2 wild-type (WT) lymphomas also arise from EZH2-dependent cells and the biological response to the EZH2 inhibitors is expected to occur in these WT tumors as well. Here, EZH2 is linked to lymphoma.